None listed
Conditions
Interventions
Drug : Intravitreal administration of 2.0 mg Aflibercept was administered to single-group subjects as the first treatment at Visit 2, and 2.0 mg Aflibercept was released twice at 4-week intervals dur
Sponsors
Kyung Hee University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Active choroidal neovascularization confirmed by optical coherence tomography angiography or fluorescein angiography and indocyanine green angiography - When the subretinal fluid accompanied by irregular elevation of the retinal pigment epithelium is confirmed by optical coherence tomography - In cases where choroidal neovascularization is observed in optical coherence tomography angiography or fluorescein angiography and indocyanine green angiography 2. Male or female patients over 50 years of age who have signed the informed consent form 3. In the absence of active ocular or systemic disease 4. Patients who understand the process of this clinical trial, are cooperative, and are judged to be able to participate by the end of the clinical trial
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women 2. Patients participating in other clinical trials 3. If patient have received anti-vascular endothelial growth factor treatment within the last 90 days 4. If patient have received photodynamic therapy 3 times or more or within the last 90 days 5. Clinically prominent diabetic retinopathy or diabetic macular edema 6. Clinically significant scar or atrophy of the fovea 7. Active Intraocular Inflammation or Infection 8. In case of hypersensitivity to Afilbercept and other ingredients in Eylea 9. History of intravitreal triamcinolone injection treatment within the last 3 months 10. History of intravitreal dexamethasone injection treatment within the last 6 months 11. History of use of inhaled or sprayed or dermal steroids for more than 30 consecutive days within the last 3 months 12. History of eye surgery, including vitrectomy, glaucoma surgery, and scleral buckling within the last 3 months (Excluding simple cataract surgery and vision correction surgery) 13. Diagnosed with retinal vascular disease other than age-related macular degeneration 14. Cerebrovascular disease, myocardial infarction diagnosed within the one year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity | — |
Secondary
| Measure | Time frame |
|---|---|
| Choroidal neovascularization, retinal pigment epithelial detachment, subretinal fluid change and central subfield thickness change | — |
Countries
Korea, Republic of
Contacts
Public ContactKyungSuk Yeo
Kyung Hee University Hospital
Outcome results
None listed